MedTrace Logo

Timing of Resective Surgery After Neoadjuvant Chemoradiotherapy in Esophageal Cancer

NCT02415101 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 202

Last updated 2025-09-03

No results posted yet for this study

Summary

This study compares outcomes with regard to the timing of resective surgery after neoadjuvant chemoradiotherapy (CRT) in cancer of the esophagus or gastric cardia. Patients are randomised to surgery either conventional 4-6 or 10-12 weeks after termination of CRT. The study hypothesis is that a longer delay improves histological response and decreases the risk of postoperative morbidity and mortality.

Conditions

  • Cancer of the Esophagus

Interventions

PROCEDURE

Resective surgery

Sponsors & Collaborators

  • Oslo University Hospital

    collaborator OTHER

  • Lund University Hospital

    collaborator OTHER

  • Sahlgrenska University Hospital

    collaborator OTHER

  • Region Örebro County

    collaborator OTHER

  • University Hospital, Umeå

    collaborator OTHER

  • St. Olavs University Hospital

    collaborator UNKNOWN

  • University Hospital, Linkoeping

    collaborator OTHER

  • University Hospital of North Norway

    collaborator OTHER

  • University Hospital Cologne

    collaborator UNKNOWN

  • Karolinska University Hospital

    lead OTHER

Principal Investigators

  • Magnus Nilsson, Prof · Karolinska University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2019-04-19
Completion
2024-08-05

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02415101 on ClinicalTrials.gov